Abbott Directed to Provide Prescribing Details for Triamcinolone Hexacetonide Pre-Filled Syringe
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has instructed Abbott Healthcare Pvt. to submit proposed prescribing information and supporting data for Triamcinolone Hexacetonide Injectable Suspension USP 40 mg/2 ml.
This directive follows a detailed review of the company's proposal during the SEC meeting on September 17, 2025, at CDSCO headquarters in New Delhi.
- Abbott presented its proposal for introducing Triamcinolone Hexacetonide Injectable Suspension USP 40 mg/2 ml Pre-filled Syringe for use in already approved indications.
- The firm submitted a detailed justification of the rationale and clinical need for this new pre-filled syringe presentation of the drug.
No specific quotes were provided in the given text.
Abbott must provide the required information to proceed. Author summary: Abbott directed to submit data.
More News
- How former Gonzaga stars perform in NBA
- Jack Osbourne breaks silence on jungle feud with Kelly Brook
- Pelicans' Questionable Offseason Trade Looks Better After Saddiq Bey's Rise
- Kelly Osbourne — Instagram Snapshot
- Guadeloupean artist Kelly Sinnapah Mary wins French art prize at Art Basel Miami Beach
- Spurs' Kelly Olynyk: Ongoing Decline in Playing Time and Role
- Hamilton urges Ferrari to make 'personnel changes' ahead of F1 2026
- When does 2026 F1 season start?
- Islanders vs. Lightning (Dec 6, 2025) Pregame
- NBA: Spurs at Timberwolves